4 years ago

EnteroBiotix Secures $21M Series A Funding for Microbiome Drug Pipeline

  • EnteroBiotix, a Glasgow-based biopharmaceutical company, raised $21m in Series A funding to further advance its microbiome drug pipeline and grow its headcount to 50.

      • ProblemHealthcare

      "Current treatments for gut health conditions often have limited efficacy and can have unwanted side effects."

      Solution

      "EnteroBiotix is developing novel drugs that harness the power of the gut microbiome to treat a range of diseases. They are developing a pipeline of products that can modulate the gut microbiome to improve health outcomes."

      Covered on